feasibility of immunotherapy in children with high-risk neuroblastoma

feasibility of immunotherapy in children with high-risk neuroblastoma - Immunotherapy in children with HR NBL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33301

Enrollment

Registered

2010-03-03

Start date

2010-10-19

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunotherapy

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: High risk neuroblastoma, between 1 and 21 years at diagnosis. Neuroblastoma histological proven diagnosis informed consent Initial staging of the tumor No pregnancy

Exclusion criteria

Exclusion criteria: Any prior or concomitant non-protocol anticancer treatment

Design outcomes

Primary

Measure	Time frame
If the BM sample is infiltrated by NBL cells, the expression of activating NK cell receptor ligands on the tumor itself; such as MIC (MICA/B) and ULBP (ULBP1-4) proteins and CD112/ -CD155 as well as the expression of HLA class I (inhibitory ligand), CD54/ -CD58 (adhesion) will be evaluated by FACS analysis using multiple markers. NK cell sensitivity will be determined by labelling primary NBL cells with 51- Chromium or by chemo luminescent methods and adding resting and cytokine activated NK cells. Furthermore, if NK cell cytotoxicity occurs, activating NK cell receptors will be blocked by monoclonal antibodies (NKG2D, DNAM-1), thereby allowing analysis of the activating signals involved. Peripheral blood samples of newly diagnosed, untreated NBL patients will allow analysis of NK cell phenotype and function in these patients at time of diagnosis.	—

Measure

Time frame

If the BM sample is infiltrated by NBL cells, the expression of activating NK cell receptor ligands on the tumor itself; such as MIC (MICA/B) and ULBP (ULBP1-4) proteins and CD112/ -CD155 as well as the expression of HLA class I (inhibitory ligand), CD54/ -CD58 (adhesion) will be evaluated by FACS analysis using multiple markers. NK cell sensitivity will be determined by labelling primary NBL cells with 51- Chromium or by chemo luminescent methods and adding resting and cytokine activated NK cells. Furthermore, if NK cell cytotoxicity occurs, activating NK cell receptors will be blocked by monoclonal antibodies (NKG2D, DNAM-1), thereby allowing analysis of the activating signals involved. Peripheral blood samples of newly diagnosed, untreated NBL patients will allow analysis of NK cell phenotype and function in these patients at time of diagnosis.

—

Countries

Netherlands

Outcome results